Search PubMed⌕ Search

Biomedical subjects

H I Atrah

Publications and source records attributed to H I Atrah.

29 records · Page 2Linked to original sources
PubMed1987

In vivo and in vitro blocking of human lymphocyte Fc gamma-receptors by intravenous gammaglobulin.

Lymphocyte subpopulations were measured in patients with idiopathic thrombocytopenic purpura before and immediately after high dose intravenous gammaglobulin (IV-IgG) therapy. A significant relative and absolute reduction in the Fc gamma-receptor bearing lymphocyte subpopulation was observed in 5 out of 7 patients tested. In vivo modulation of lymphocyte Fc gamma-receptors therefore probably occurs: an effect which may be attributable to the Fc gamma R-blocking anti-lymphocytic antibodies found in IV-IgG preparations. In vitro studies showed that IV-IgG preparations also contain antibodies with the capacity to block Fc gamma-receptors on human monocytes and polymorphs and that these antibodies can inhibit the T cell response to phytohaemagglutinin. These anti-lymphocyte antibodies may be important in the mode of action of high dose IV-IgG therapy.

Aged↗
PubMed1986

Improvement of post platelet transfusion increments following intravenous immunoglobulin therapy for leukaemic HLA-immunized patients.

3 patients with acute leukaemia, HLA antibodies and thrombocytopenia refractory to random donor platelet transfusions were treated with high-dose i.v. immunoglobulin. All 3 patients responded favourably with improved post-transfusion recovery of random platelets. In 1 patient, the recovery of transfused histocompatible platelets was also enhanced. Treatment was followed by reduction in the total lymphocyte count and marked changes in lymphocyte subsets in 1 patient.

Adult↗
PubMed1986

Intravenous immunoglobulin therapy for idiopathic thrombocytopenic purpura.

Twenty-two patients with idiopathic thrombocytopenic purpura were treated with high-dose intravenous immunoglobulin infusions using an intact intravenous immunoglobulin preparation and a product designed for intramuscular administration. Seventeen patients (77%) responded favourably (rise in platelet count to 100 X 10(9)/1 or above). Children responded better than the adults, and the acute cases better than the chronic. Splenectomy and the presence of detectable platelet antibody had no effect on the response rate. Both products induced identical responses.

Acute Disease↗
PubMed1985

Successes and failures of intravenous immunoglobulin.

11 patients suffering from primary and secondary severe haematological disorders of possible immune origin were treated with high-dose intravenous immunoglobulin. The responses obtained were partial in 3 and negligible in 8.

Adult↗
PubMed1985

Safety of intravenous immunoglobulin treatment.

In a prospective clinical and biochemical study of 16 patients treated with high doses of an immunoglobulin product that had been modified for intravenous use by mild pepsin treatment at pH 4 no evidence of hepatitis could be found. This contrasts with recent reports that intravenous immunoglobulin products can apparently transmit non-A, non-B hepatitis.

Alanine Transaminase↗
PubMed1985

Iron status in hypogammaglobulinaemia.

Iron, transferrin and ferritin were measured in serum samples from 16 patients with primary hypogammaglobulinaemia. Transferrin saturation was low in 12 patients (75%) and serum ferritin was low in 9 patients (56.25%). Both parameters were low, confirming the state of iron deficiency, in 6 patients (37.5%). These figures are highly significant (P less than 0.01) when compared with the prevalence of iron deficiency in the general population. Eight patients were maintained on intravenous immunoglobulin infusions and the rest on intramuscular immunoglobulin injections, their mean serum IgG being 4.4 g/l and 2.6 g/l respectively. There was no difference in the prevalence of iron deficiency between the two groups.

Adolescent↗